Guidelines on the treatment of asthma, allergic rhinitis (AR), and allergen immunotherapy (AIT) lack recommendations for house dust mite (HDM) allergy. An expert panel reviewed current guidelines in the light of new data to assess whether guidelines could be improved. Most guidelines and key position papers did not provide specific recommendations on treatment of allergic asthma (AA) caused by HDM allergy, although some included AIT as a treatment option for AA in general. Around half of the guidelines stated that AIT with HDM extract was an effective treatment for AR, with several indicating sublingual immunotherapy as an option. This heterogeneity is caused by quality issues affecting studies of AIT with perennial allergens in patients with AA and AR, including use of different diagnosis and severity criteria, lack of consistent scoring or grading systems for primary and safety outcomes, and lack of consensus on treatment parameters. There is a need for well-designed clinical trials to serve as a basis for guideline recommendations. Although results from recent studies strengthen the evidence base for the efficacy and safety of sublingual immunotherapy in patients with HDM-induced AA and AR, their effect on subsequent guideline updates will depend on the methodology and evidence model used by each guideline. (J Allergy Clin Immunol 2017;140:41-52.) 
Despite house dust mite (HDM) allergy being a major cause of respiratory allergic disease and often implicated as a trigger for asthma and perennial allergic rhinitis (AR), specific treatment guidance for AR and allergic asthma (AA) caused by HDM are not well defined to date. The choice of allergen-specific treatment for patients with HDM allergy is not facilitated by recommendations in current national and international allergen immunotherapy (AIT) guidelines. Most guidelines focus on treatment of AR or AA, regardless of the type and number of sensitizing allergens, rather than on the cause, with the assumption that all respiratory allergies are the same. Because approximately 50% of patients with HDM-induced AR also have AA, support to clinicians is needed for integrated management. Although guidelines written by allergists widely support the use of AIT in patients with AR, its use in patients with AA or AR with AA is contentious, as demonistrated in the current review. Some guidelines consider that level of efficacy, adverse effects, and resource expenditure associated with AIT to be completely offset the clinical benefit, whereas others perceive it as cumbersome and costly and recommend its use only as last-line treatment. [1] [2] [3] In clinical practice, the choice of sublingual versus subcutaneous administration is ultimately determined by patient and doctor preferences.
An expert panel was convened to review the recommendations of the current treatment guidelines on the use of AIT and sublingual immunotherapy (SLIT) in patients with AA and AR caused by HDM allergens identified by searching the literature. Based on this and the panel's clinical expertise, the authors propose how the guidelines could be improved for general use and ask whether it is time to re-evaluate the available evidence in light of recent new data in both HDM-induced AA and AR that report favorable safety and efficacy profiles for SLIT tablets in adults. 4, 5 
GUIDELINE RECOMMENDATIONS ON USE OF ALLERGEN IMMUNOTHERAPY IN PATIENTS WITH HOUSE DUST MITE ALLERGY Specific guideline recommendations for AR
All reviewed guidelines on treatment of AR included AIT as a possible treatment for selected patients with AR (Table  I) . 3, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Some specified that AIT with HDM extracts was effective in both adults and children. [6] [7] [8] Several guidelines included SLIT as an option for treatment of AR in adults 6 or both adults and children, [9] [10] [11] and some specified that SLIT with HDM allergens was effective and safe in patients with AR. 3, 7, 12 The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines gave a conditional recommendation for both subcutaneous immunotherapy (SCIT) and SLIT in patients with AR caused by HDM allergy because of the moderate quality of the available evidence in adults, and the low-quality evidence in children. 6 Specific guideline recommendations for patients with AA Several asthma guidelines and key position papers include AIT as a treatment option for AA (Table II) . [1] [2] [3] 7, 10, [14] [15] [16] [17] [18] [19] [20] [21] Some advise that SCIT [16] [17] [18] with HDM extract is an effective treatment for AA caused by HDM allergy, and one specified that SLIT has an effect on inflammation and bronchial hyperreactivity in asthmatic children sensitized to HDM 18 ; however, most did not provide specific information on the treatment of HDM-induced AA.
We did not find a consensus among the current guidelines on treatment of AA by AIT. Of the guidelines reviewed, most included AIT as a treatment option for persistent asthma in selected adults 7, 10, 16, 19 and children 7, 10, [16] [17] [18] [19] [20] and in patients with AR and AA 6 in addition to pharmacotherapy. In some cases allergen avoidance measures and asthma education are recommended when there is clear evidence of a relationship between symptoms and exposure to an allergen. The use of AIT for AA was more widely supported in children than in adults, which appears to be based on data showing that the role of allergy in asthmatic patients is greater in children 17 and not based on the number of AIT trials in this population group.
The most recent asthma guidelines from the British Thoracic Society state that SCIT or SLIT are not recommended for the treatment of asthma in children or adults, 2 and the Global Initiative for Asthma (GINA) 2016 guideline states that the efficacy of AIT in asthma is limited. 1 
Evidence base for guideline recommendations
Most of the guidelines reviewed were evidence-based. Some made recommendations based largely on published systematic reviews and meta-analyses, 2 whereas others, such as ARIA, performed meta-analyses where possible and evaluated the quality of the underlying evidence. Some, but not all, guidelines used evidence models, such as GRADE, 6, 22 SIGN, 2,9,23 Shekelle, 7, 9 or the American Academy of Pediatrics classification scheme. 13 The quality of evidence for a clinically beneficial effect of AIT in patients with AR was higher than for those with AA. Factors that decreased the quality of the body of evidence supporting the use of AIT in patients with AA included difficulty quantifying the effect of AIT because of heterogeneity in study design and reporting of outcomes, 2,3 small clinical benefits, 1, 20 small benefits at the expense of significant adverse effects, 2 and the cost of prolonged treatment. 1 Guidelines on AR cited findings of meta-analyses on both SCIT and SLIT and well-conducted randomized controlled trials showing reduced symptom and medication scores and possible modification of the disease course. The ARIA guideline suggestion for the use of SLIT in adults, but not children, with HDMinduced AR was based on moderate-quality evidence and placed a relatively high value on avoiding adverse effects of SLIT in children and reducing resource expenditure, and a relatively low value on a possible small reduction in nasal symptoms. 6 To date, the most comprehensive analysis of the efficacy of SLIT for HDM-induced AR and AA is the GA 2 LEN meta-analysis. 24 Although the authors found beneficial effects of SLIT with HDM extract in patients with AR and AA, they noted a significant clinical and methodological heterogeneity between the studies. Only the 2014 British Thoracic Society asthma guideline 2 cited this most recent meta-analysis.
Specific quality issues affecting AIT trials with perennial allergens in patients with AA and AR Although the AA endotype has been well defined, 25, 26 this definition encompasses a wide range of disease etiology, severity, and treatment responses. Approximately half of adult asthmatic patients are allergic to common and relevant airborne allergens. 27 Depending on the study inclusion criteria, this leads to significant heterogeneity in study populations. Moreover, there are differences among allergens concerning important factors, such as the degree and type of exposure (eg, seasonal, perennial, and occupational), enzymatic content, and so on.
Importantly, there are no universally accepted endpoints for studies of AIT in patients with AA. The recent revision of the European Medicines Agency (EMA) ''Draft note for guidance on the clinical investigation of medicinal products for treatment of asthma'' 28 includes considerations for AIT development in asthmatic patients, suggesting lung function, composite scores, number of exacerbations, or reduced need for controller medication as primary endpoints. Clinical relevance of the primary efficacy measure should be specified. Likewise, there is currently no validation of the proposed standardization of clinical outcomes used in AIT trials in patients with AR, 29, 30 and few include follow-up assessments of long-term efficacy. In addition, there is variability in the potency and composition of the allergen extracts used in different studies, which stems from differences in source material and standardization between manufacturers.
The onset and duration of exposure to perennial allergens can vary significantly over the annual period. 29 HDM AIT studies start at different times of the year and have differing durations, 30 and therefore allergen exposure during a study is unknown because few studies measure levels of HDM allergens or use provocation tests. 29, 30 Even when provocation testing is used, there is no standardization between studies. 29 Moreover, for a large Phase III trial, provocation tests are likely to be impossible to implement.
A recent evidence-based analysis of SLIT for HDM-induced AR and AA highlighted the lack of consensus on basic treatment parameters (eg, dose and duration) between studies. 31 A comprehensive review of AIT for the treatment of AR, asthma, or both by the US Agency for Healthcare Research and Quality found moderate clinical effects of SLIT in children with mildto-moderate persistent AA caused by HDM allergy, but not with AR, and noted a great deal of heterogeneity in the literature reviewed, 32 including:
d varying criteria for diagnosing asthma and assessing asthma severity and control; d lack of consistent scoring or grading systems for reporting primary outcomes; d deficiencies in statistical reporting; d lack of a consistent reporting and grading system for adverse outcomes, which made it impossible to pool safety data across studies; and d lack of information because of publication bias.
Moreover, because the quality of reporting of most AIT trials does not consistently meet CONSORT criteria for the reporting of randomized trials, 33 it is often difficult to assess how closely available guidance was followed (see Table III 34 for EMA guidance for trials in patients with perennial AR, AA, or both). Many trials were performed and published before this guidance was launched; however, recent and future trials should no longer have these drawbacks.
The 2014 update of the World Allergy Organization position paper on SLIT also found that the conclusions of the available meta-analyses on SLIT are limited by heterogeneity of allergen doses, duration of treatment, and patient selection between studies, and noted that the quality of systematic reviews and meta-analyses of SLIT could be improved by considering heterogeneity and increasing transparency. 12 A recent evaluation of meta-analyses of SLIT for patients with AA and those with AR casts doubt on the robustness of previous meta-analyses citing inconsistencies in study design and variable study quality. 35 Meta-analyses pool data from heterogeneous studies, such as SLIT studies with different allergens, which might lead to the conclusion that all related AIT products are effective. The result is that many untested products for AIT are available on the market as named patient products. However, guidelines are more likely to value conventional product development through phases I to III rather than class development. Until now, there has been a lack of robust data on the efficacy and safety of products for AIT for AR and AA caused by HDM allergy through conventional product development.
These concerns about the quality of the evidence base have led many to call for better designed, rigorous, long-term, placebocontrolled, randomized clinical trials 24, [30] [31] [32] 36 using standardized products. Moreover, the World Allergy Organization recently called for a move toward product-based evaluation, indicating that the heterogeneous quality of evidence for individual AIT products makes overall conclusions on routes of delivery or ''class effects'' unjustified. 37 
EVIDENCE NEEDED TO SUPPORT AIT TREATMENT RECOMMENDATIONS FOR HDM ALLERGY IS EMERGING
The recently published outcomes of large, randomized, doubleblind, placebo-controlled AIT field studies in patients with In a large trial by Bergmann et al, 38 300IR and 500IR HDM sublingual tablets significantly reduced mean average adjusted symptom scores in adults with AR by 217.9% (P 5 .0150) and 220.2% (P 5 .0066), respectively, compared with placebo, with efficacy maintained during a treatment-free follow-up year. Treatment was well tolerated, with no difference in the safety profile between active treatment groups. The most commonly reported SLIT-emergent adverse events were oral pruritus, throat irritation, and mouth edema, which were generally mild to moderate in intensity.
In the study by Virchow et al, 5 up to 18 months of treatment with 2 doses (6 SQ-HDM and 12 SQ-HDM) of the SQ HDM SLIT tablet in patients with HDM-induced AA significantly reduced the risk of moderate or severe asthma exacerbation compared with placebo during an inhaled corticosteroid (ICS) reduction period (risk reduction, 31% and 34%; hazard ratio [full analysis set], 0.69 and 0.66; P 5 .03 and .02, respectively). Treatment was well tolerated, and there were no safety findings of clinical concern, even in a group of patients whose symptoms were uncontrolled according to GINA classification at randomization (while still fulfilling the inclusion criteria on lung function of FEV 1 of > _70% of predicted value and no severe exacerbations within 3 months). 5 Thus, among adults with HDM allergy-related asthma not well controlled by ICSs, HDM SLIT tablets significantly prolonged the time to the first asthma exacerbation during ICS reduction. To our knowledge, this is the first study specifically showing an effect with AIT on asthma exacerbations in this subset of patients.
Demoly et al 4 reported that in adults with moderate-to-severe persistent HDM-induced AR, 6 SQ-HDM and 12 SQ-HDM significantly reduced the total combined rhinitis score (TCRS) at all timepoints from 14 weeks to approximately 1 year of treatment (absolute reduction in TCRS vs placebo; prespecified minimal clinically important difference [MCID], 1.18 [P 5 .002] and 1.22 [P 5 .001] for 6 SQ-HDM and 12 SQ-HDM, respectively). In relative terms, based on adjusted mean and median reductions in TCRS for the 12 SQ-HDM dose, this corresponds to 18% to 22%. 4 The safety profile of both doses was appropriate for home administration after the first dose was taken under medical supervision; the most frequently reported adverse events were oral pruritus, throat irritation, and mouth edema that abated within minutes to hours. 4 Key questions that can be raised for any clinical trial touch on the clinical relevance of outcomes and on whether enrolled subjects reflect those encountered in everyday clinical practice. This depends on the choice of primary and secondary endpoints and on study limitations (eg, patient inclusion criteria, severity of asthma, and degree of asthma control). In the study summarized above by Virchow et al, 5 the choice of a primary endpoint based on exacerbations during ICS reduction is a novel approach in AIT trials. As mentioned above, there are no universally accepted endpoints for AIT trials in patients with AA. An MCID has been proposed for some AR clinical endpoints 41 but this was calculated based on studies that were not AIT studies of patients with HDM-associated AR and that did not use average adjusted symptom scores. As such, there are to date no data defining an MCID for the average adjusted symptom score in these patients, and therefore this needs to be specified and argued for by each drug developer.
COULD DATA FROM NEW, WELL-DESIGNED, HIGH-QUALITY STUDIES PROVIDE SUFFICIENT EVIDENCE FOR A RECOMMENDATION IN GUIDELINES?
Well-designed and well-conducted trials are a key step in obtaining regulatory approval for new treatments; however, trial populations do not always closely represent the type of patients encountered in routine care. 42 More than half of asthmatic patients do not achieve control with their current pharmacotherapy, and even patients with well-controlled asthma experience, on average, 6 worsenings per year (defined as occasions when asthma symptoms were bothersome or hindering). 43 Similarly, not all patients with AR have their symptoms fully controlled by pharmacotherapy (up to 13% are uncontrolled in one study 44 ). In the MT-04 study by Virchow et al, 5 symptoms of patients with AA were not well controlled based on Asthma Control Questionnaire scores of 1 to 1.5 at randomization, and 28% of subjects had uncontrolled symptoms according to GINA criteria, as mentioned above. 45 In MT-06 by Demoly et al, patients' AR at inclusion was not well controlled because they had a high level of symptoms and effect on their quality-of-life despite the use of pharmacotherapy. Therefore, the choice of study population for these studies is in line with the high unmet need in patients who do not have wellcontrolled disease. The design of these recent studies complies with EMA guidance on the clinical development of products for AIT (Table III) , 34 and the design and primary endpoint of MT-04 are in line with the latest EMA guidance on AIT products intended to modify the immunologic mechanism underlying AA. 28 Efficacy and safety data meet the demands for robust evidence from well-conducted, randomized clinical trials called for in guidelines, reviews, and meta-analyses. The ARIA guideline noted that new data from rigorously designed and executed randomized trials of SLIT in children would likely have an important effect on recommendations for the use of SLIT in children with AR without AA and for patients with AR and AA. 6 The effect of these new results on guideline recommendations remains to be seen and will depend on the methodology and evidence model used by the different guidelines. However, adoption can take several years; publication of 3 studies on tiotropium in 2010, 2011, and 2012 led to their addition to GINA guidelines only in 2015, and 2 studies of mepolizumab published in 2009 and 2012 led to their appearance in GINA guidelines in 2016. 1 Nevertheless, these new outcomes discussed above strengthen the evidence base for the efficacy and safety of the HDM SLIT tablet in patients with AA, AR, or both and are an important step toward the possible inclusion of this treatment option in future guideline updates.
CONCLUSIONS
Even though AIT was first described more than a century ago and up to 50% of patients with HDM-induced AR also have AA, specific treatment recommendations for AIT in patients with AA, AR, or both caused by HDM allergy remain unclear. This has largely been due to the relatively low quality of the body of evidence supporting the use of AIT in this context, which has complicated quantification of AIT's effect. Reasons include heterogeneity in study design and reporting of outcomes, a lack of universally accepted end points and MCID estimates, and differences in the efficacy of allergen preparations in different trials.
Recent data in patients with HDM-induced AA with the SQ-HDM SLIT tablet and in those with HDM-induced AR with 2 different HDM SLIT products reporting favorable safety and efficacy profiles in adults come from studies that conform to current guidance and mark a step toward product-based evaluation. These data, together with the outcomes of further welldesigned trials powered to show clinically relevant superiority in comparison with conventional pharmacotherapy with topical corticosteroids and antihistamines, will serve as a basis for future guideline recommendations. In studies of AR, use of rescue medication has an effect on symptom severity. Therefore the primary end point has to reflect both symptom severity and used rescue medication. d End points should be evaluated several times during the treatment for perennial allergies and at least at the end of follow-up.
